Urinary cytology screening is used for inflammatory diseases, precancerous conditions, and cancer. Cytology has a high specificity of 98% in the diagnosis of bladder cancer.

Implementation of The Paris System for Reporting Urinary Cytology was adopted and used primarily to lower atypical diagnostic rates, focus on high-grade screening and provide our clinicians with a more efficient and diagnostic way of reporting and treating a patient.

hTERT Antibody ICC – To enhance our highly specific cytology testing, we have added an FDA-approved biomarker that aids in the detection of bladder cancer.

Contains a cancer-related biomarker known as telomerase. The addition of Anti-hTERT ICC is crucial in patient care with the knowledge that 90% of bladder cancers use telomerase. When this antibody stains positive, it indicates an increased chance of urothelial cancer (including pre-invasive urothelial proliferation and invasive cancer).

Urine specimens may be submitted to test for sexually transmitted infections. Our testing method is through Transcription Mediated Amplification or (TMA) PCR. We currently offer STI testing to both males and females to include:

• Chlamydia trachomatis
• Neisseria gonorrhea
• Trichomonas vaginalis
• Mycoplasma genitalium